Argyrios Tzouvelekis, PhD | American Lung Association

Location Select your location

Argyrios Tzouvelekis, PhD

Research Awards Nationwide Recipient (2014-2016)

Yale University
Funded by the American Lung Association of the Northeast
Enzyme Could Play Key Role in Idiopathic Pulmonary Fibrosis

Idiopathic pulmonary fibrosis (IPF) is a devastating chronic lung disease in which lung tissue becomes scarred over time in response to unknown injuries. This leads to shortness of breath and dry cough that gradually progresses, culminating in death in 3-5 years. The IPF lung is characterized by increases in cells in the lung called fibroblasts. We have discovered an enzyme called SHP-2 is decreased in the lung fibroblasts of patients with IPF. We will study whether reduced levels of SHP-2 from the lungs of patients with IPF render them susceptible to disease development, and whether restoring its levels in a mouse model of lung fibrosis may exert a therapeutic role.

Ask An Expert

Questions about your lung health? Need help finding healthcare? Call 1-800-LUNGUSA.

Get help
We need your generous support

Make a difference by delivering research, education and advocacy to those impacted by lung disease.

What is LUNG FORCE?

LUNG FORCE unites women and their loved ones across the country to stand together in the fight against lung cancer.

Get involved
Join the fight for healthy lungs and healthy air.
Donate Now.